is phentermine a glp-1 agonist Anti-Obesity medications (Mechanism of Action) – My Endo Consult Weight loss with Semaglutide &

GLP-1RAs cardiovascular advantages have resulted in their preference as second-line treatment for T2DM patients who already have established atherosclerotic cardiovascular disease

In the SURMOUNT-5 head-to-head against semaglutide, tirzepatide produced 47% greater relative weight loss

Across sex subgroups, effects were similar for semaglutide versus sitagliptin and for tirzepatide versus semaglutide whereas for tirzepatide versus dulaglutide, estimates suggested male patients to benefit more from tirzepatide than female patients

The list of FDA-approved indications for this class of medication has grown as of late (and currently includes type 2 diabetes, obesity, cardiovascular event risk reduction, obstructive sleep apnea, chronic kidney disease, and metabolic dysfunction-associated steatotic liver disease), and areas of interest for potential future indications are just as long and farreaching

Non-arteritic anterior ischemic optic neuropathy (NAION) is a rare eye condition that occurs when blood flow to the optic nerve becomes restricted, causing damage to the nerve fibers that transmit visual information from the retina to the brain

Nevertheless, the dual mechanism of action of tirzepatidecombining GLP-1mediated appetite suppression with GIP-driven improvements in insulin sensitivity and lipid metabolismrepresents a promising therapeutic strategy that warrants further investigation in adolescent-specific clinical trials